Update on the management of ulcerative colitis

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Current treatment goals for inflammatory bowel diseases (IBD), particularly ulcerative colitis (UC), emphasize rapid clinical remission, steroid-free maintenance, mucosal healing, and improved quality of life.
• Immunomodulators like azathioprine/6-mercaptopurine are typically reserved for steroid-dependent or refractory UC, primarily for remission maintenance in quiescent disease.
• Calcineurin inhibitors offer short-term rescue for steroid-refractory UC, but their long-term efficacy is not well-established.

Purpose of the Study:

• To review current treatment strategies for ulcerative colitis (UC).
• To evaluate the role of conventional therapies, including immunomodulators and calcineurin inhibitors.
• To discuss the emerging potential of novel biological therapies in managing IBD.

Main Methods:

• Review of existing literature on UC treatment modalities.
• Analysis of the efficacy and limitations of immunomodulators and calcineurin inhibitors.
• Examination of the current and potential future applications of biological therapies in IBD.

Main Results:

• Azathioprine/6-mercaptopurine are recommended for maintaining remission in quiescent UC.
• Methotrexate is not advised for inducing or maintaining remission in UC based on retrospective data.
• Infliximab is approved for moderate-to-severe active UC unresponsive to conventional therapies, while other biologics are under investigation.

Conclusions:

• Biologic therapies are increasingly important for IBD management, with infliximab used for active UC.
• Long-term treatment with biologics is generally recommended, and discontinuation consequences should be discussed.
• Emerging data suggest biologics may prevent complications and disease progression, potentially altering future treatment paradigms for UC and IBD.